Man Banned Five Years from Importing Any U.S. Drugs
Published Date: 7/24/2026
Notice
Summary
Francis Esteban Matos is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime related to drug importation. He didn’t respond to the FDA’s notice, so the ban started on July 24, 2026. Matos can apply to end this ban anytime, but he must follow specific rules to do so.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Five‑Year Drug Import Debarment
Francis Esteban Matos is banned for 5 years from importing or offering for import any drug into the United States, effective July 24, 2026. The debarment follows his October 14, 2025 felony conviction for conspiracy to introduce misbranded drugs into interstate commerce.
Importing With Matos Is Prohibited
During the 5‑year debarment, importing or offering for import any drug 'by, with the assistance of, or at the direction of' Mr. Matos is a prohibited act under the FD&C Act (see section 301(cc)).
You Can Apply To End Debarment Anytime
Mr. Matos may submit an application to terminate debarment under section 306(d)(1) at any time. Applications submitted electronically to https://www.regulations.gov (Docket No. FDA-2026-N-1199) will be posted publicly unchanged; confidential information must be submitted as a written/paper submission following the notice's instructions.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14984, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Prognostic Test for Assessment of Chronic Kidney Disease Progression
The FDA is officially putting a special kidney disease test into Class II, meaning it’s safe and effective but with some extra rules to keep it that way. This change helps patients get access to this cool new test faster by cutting down red tape. The new classification is effective July 24, 2026, and could save companies time and money while making sure the test works well.
2026-15021, Evonik Corporation, Filing of Food Additive Petition (Animal Use)
Evonik Corporation has asked the FDA to approve ethyl cellulose as a safe binder and coating for amino acids in food for ruminant animals like cows and sheep. This change could improve animal feed quality without extra costs or delays, with the petition officially filed on June 16, 2026. Farmers and feed producers should keep an eye out as this could soon become part of the rules.
2026-14986, Medical Devices; General Hospital and Personal Use Devices; Classification of the Diabetes Digital Behavioral Therapeutic Device
The FDA has officially placed the diabetes digital behavioral therapeutic device into Class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification took effect on July 24, 2026, with benefits starting from July 7, 2023, making it easier and potentially cheaper for makers to bring these devices to market.
2026-14985, Medical Devices; Immunology and Microbiology Devices; Classification of the Over-the-Counter Test To Detect SARS-CoV-2 From Clinical Specimens
The FDA is officially putting over-the-counter COVID-19 tests into a safer, easier-to-manage category called Class II, starting July 24, 2026. This change helps make sure these tests work well and are safe, while also making it simpler for companies to bring new tests to you. If you’re a test maker or a user, expect better access and less red tape, with no extra costs announced.
Previous / Next Documents
Previous: 2026-14982, Agency Information Collection Activities; Comment Request; Approved State Ability To Benefit Process
The Department of Education wants to keep collecting info about how states check if students can benefit from federal student aid, without changing anything. This affects students and schools involved in federal aid programs and helps keep the process smooth. You’ve got until September 22, 2026, to share your thoughts—no cost changes, just a paperwork check-in!
Next: 2026-14995, National Wildlife Refuge System; Request for Information on Implementation of Drain Tile Setbacks
The Fish and Wildlife Service wants your thoughts on how they decide where landowners can place drain tiles near wetlands they protect. This affects landowners with wetland easements and could change how close drain tiles can be to these sensitive areas. You’ve got until August 7, 2026, to share your ideas—so jump in and help shape the rules!